Table 1.
Limiting dilution transplants of MMTVrtTA/H2BGFP populations
| Population | Number of cells | Number of glands | MRU frequency (confidence interval) |
|---|---|---|---|
|
Virgin recipients | |||
|
a. H2GFP
+
/CD24
+
/CD29
+
|
10 |
3/16 |
1/105 (70 - 160) |
| |
20 |
5/12 |
|
| |
50 |
3/12 |
|
| |
100 |
6/10 |
|
| |
200 |
9/12 |
|
|
b. H2GFP
-
/CD24
+
/CD29
+
|
10 |
2/12 |
1/80 (60 - 130) |
| |
20 |
2/14 |
|
| |
50 |
5/12 |
|
| |
100 |
9/12 |
|
| |
200 |
9/10 |
|
|
c. H2GFP
+
/CD24
+
/CD29
lo
|
10 |
0/14 |
1/1,600 (500 - 4,900) |
| |
20 |
0/12 |
|
| |
50 |
0/12 |
|
| |
100 |
1/12 |
|
| |
200 |
2/14 |
|
|
d. H2GFP
-
/CD24
+
/CD29
lo
|
10 |
0/14 |
None |
| |
20 |
0/12 |
|
| |
50 |
0/12 |
|
| |
100 |
0/14 |
|
| |
200 |
0/14 |
|
|
+ Pregnancy | |||
|
e. H2GFP
+
/CD24
+
/CD29
+
|
10 |
1/4 |
1/60 (35 - 100) |
| |
20 |
3/6 |
|
| |
50 |
5/8 |
|
| |
100 |
5/8 |
|
| |
200 |
6/6 |
|
|
f. H2GFP
-
/CD24
+
/CD29
+
|
10 |
3/8 |
1/140 (80 - 240) |
| |
20 |
3/6 |
|
| |
50 |
2/8 |
|
| |
100 |
4/8 |
|
| |
200 |
4/8 |
|
|
g. H2GFP
+
/CD24
+
/CD29
lo
|
10 |
1/6 |
1/350 (160 -790) |
| |
20 |
0/8 |
|
| |
50 |
1/6 |
|
| |
100 |
1/8 |
|
| |
200 |
3/6 |
|
|
h. H2GFP
-
/CD24
+
/CD29
lo
|
10 |
0/6 |
None |
| |
20 |
0/8 |
|
| |
50 |
0/6 |
|
| |
100 |
0/6 |
|
| |
200 |
0/6 |
|
|
Virgin Recipients vs. Pregnancy - 2
nd
Experimental Set | |||
|
i. H2GFP
+
/CD24
+
/CD29
lo
|
10 |
0/14 |
1/3,800 (500 - 27,000) |
|
Virgin |
20 |
0/12 |
|
| |
50 |
1/12 |
|
| |
100 |
0/12 |
|
| |
200 |
0/8 |
|
|
j. H2GFP
+
/CD24
+
/CD29
lo
|
10 |
2/12 |
1/280 (170 - 480) |
|
+Pregnancy |
20 |
2/14 |
|
| |
50 |
4/14 |
|
| |
100 |
4/14 |
|
| 200 | 4/14 | ||
Mammary repopulating ability of H2BGFP+/CD24+/CD29+ (a, e), H2BGFP-/CD24+/CD29+ (b, f), H2BGFP+/CD24+/CD29lo (c, g, i) and H2BGFP-/CD24+/CD29lo (d, h, j) populations in virgin mice (a-d, i) and pregnant mice (e-h, j). H2BGFP, histone 2B-eGFP; MMTV, mouse mammary tumor virus promoter; MRU, mammary reproducing unit; rtTA, reverse tetracycline transactivator.